These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27692301)

  • 1. Gene therapy for sickle cell disease.
    The Lancet Haematology
    Lancet Haematol; 2016 Oct; 3(10):e446. PubMed ID: 27692301
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of Fetal Hemoglobin by Gene Therapy.
    Walters MC
    N Engl J Med; 2021 Jan; 384(3):284-285. PubMed ID: 33471981
    [No Abstract]   [Full Text] [Related]  

  • 3. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
    Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tweaking genes with CRISPR or viruses fixes blood disorders.
    Kaiser J
    Science; 2020 Dec; 370(6522):1254-1255. PubMed ID: 33303593
    [No Abstract]   [Full Text] [Related]  

  • 5. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
    N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
    Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
    Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Welcoming the Era of Gene Editing in Medicine.
    Daley GQ
    N Engl J Med; 2024 May; 390(18):1642-1645. PubMed ID: 38657270
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
    Lohani N; Bhargava N; Munshi A; Ramalingam S
    J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising Strategies for Sickle Cell Disease and β-Thalassemia.
    Abbasi J
    JAMA; 2021 Jan; 325(2):121. PubMed ID: 33433564
    [No Abstract]   [Full Text] [Related]  

  • 11. Gene therapy: Erasing sickle-cell disease.
    Bourzac K
    Nature; 2017 Sep; 549(7673):S28-S30. PubMed ID: 28953858
    [No Abstract]   [Full Text] [Related]  

  • 12. CRISPR/Cas9 system and its applications in human hematopoietic cells.
    Hu X
    Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia.
    Handgretinger R; Mezger M
    Expert Opin Biol Ther; 2024 Sep; 24(9):883-888. PubMed ID: 39222044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
    Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
    Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR in personalized medicine: Industry perspectives in gene editing.
    Hong A
    Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UK first to approve CRISPR treatment for diseases: what you need to know.
    Wong C
    Nature; 2023 Nov; 623(7988):676-677. PubMed ID: 37974039
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular scissors cut in on stem cells.
    Azvolinsky A
    Nat Med; 2019 Jun; 25(6):864-866. PubMed ID: 31086349
    [No Abstract]   [Full Text] [Related]  

  • 18. The Cas9 Hammer-and Sickle: A Challenge for Genome Editors.
    Urnov FD
    CRISPR J; 2021 Feb; 4(1):6-13. PubMed ID: 33616446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Meisel R
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107195
    [No Abstract]   [Full Text] [Related]  

  • 20. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Mehta J
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.